A Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

This study has been terminated.

First Received: November 5, 2007 Last Updated: September 11, 2008 History of Changes

Sponsor:	Abbott
Information provided by:	Abbott
ClinicalTrials.gov Identifier:	NCT00554385

Purpose

The objective of this study is to evaluate the long-term safety and tolerability of ABT-089 in children with ADHD.

Condition	Intervention	Phase
Attention-Deficit/Hyperactivity Disorder	Drug: ABT-089	Phase II

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title:	The Long-Term Safety and Tolerability of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD): An Open-Label Extension Study

Further study details as provided by Abbott:

Primary Outcome Measures:

ADHD-RS-IV (HV) [ Time Frame: Day -1, Day 14, Months 1, 2, 3, 6, 9 & 12 ] [ Designated as safety issue: No ]
CGI-ADHD-S [ Time Frame: Day -1, Day 14, Months 1, 2, 3, 6, 9 & 12 ] [ Designated as safety issue: No ]

Enrollment:	283
Study Start Date:	November 2007
Primary Completion Date:	August 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental	Drug: ABT-089 Up to 4 capsules will be taken once daily for 12 months. Dosage forms include 1 mg, 5 mg, 10 mg capsules and 40 mg tablets. Highest dose allowed is 80 mg per day.

Eligibility

Criteria

Inclusion Criteria:

The subject was randomized into Base Study (M06-888 or M10-345) and completed the Treatment Period.
If female, subject must be practicing at least one method of birth control throughout the study.
If female, the result of a pregnancy test is negative.
The subject is judged to be in generally good health.

Exclusion Criteria:

The subject experienced a serious adverse event in Base Study (M06-888 or M10-345) that the investigator considered "possibly" or "probably related" to study drug.
The subject has taken any ADHD medication between the last dose of study drug in Study M06-888 or M10-345 and the first dose of study drug in the current study.
The subject has a positive urine drug screen for alcohol or drugs of abuse.
The subject anticipates a move outside the geographic area.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00554385

Sponsors and Collaborators

Abbott

Investigators

Study Director:

Laura Gault, M.D., Ph.D.

Abbott

More Information

No publications provided

Responsible Party:	Abbott ( Laura Gault, M.D., PhD Study Director )
Study ID Numbers:	M10-178
Study First Received:	November 5, 2007
Last Updated:	September 11, 2008
ClinicalTrials.gov Identifier:	NCT00554385 History of Changes
Health Authority:	United States: Food and Drug Administration

Additional relevant MeSH terms:

Signs and Symptoms
Pathologic Processes
Disease
Attention Deficit Disorder with Hyperactivity
Mental Disorders
Nervous System Diseases

Mental Disorders Diagnosed in Childhood
Neurologic Manifestations
Attention Deficit and Disruptive Behavior Disorders
Hyperkinesis
Dyskinesias

ClinicalTrials.gov processed this record on November 30, 2009